Peptide Sciences Retatrutide: The Benchmark Meets the New Wave

Retatrutide — a triple-agonist (GIP/GLP-1/glucagon) research peptide — arrived as the third act of the GLP-1 wave: semaglutide built the market (see the sourcing analysis), tirzepatide broadened it, and retatrutide became the wave's speculative frontier. Peptide Sciences carried retatrutide listings in its final period, which made the company the default search-adjacent brand for the compound: Peptide Sciences retatrutide became a high-volume product-brand query.

The chemistry matters for the sourcing story: retatrutide is a large, complex synthesis (longer and harder than tirzepatide — see our tirzepatide channel page for the difficulty analysis), which raises the documentation bar precisely because the molecule is hard to make correctly. Identity confirmation by LC-MS is the minimum artifact for any credible lot, per the standard on high purity peptides.

Archived listings show the product carried the company's standard documentation package — lot-linked COA, method stated — the record reconstructed on the review page. What no seller could carry for this family was pharmaceutical-grade certainty: research-channel retatrutide is research material by definition, the tier boundary dissected on research purposes only. Pricing anchored to the GLP-1 family's drug-price logic, the premium analyzed on peptide price.

Today the query is a demand fossil: the company is closed (see the shutdown research), and the search persists because old threads and comparisons still route intent to the name — which imitators monetize, per the website page. We do not sell, source, or advise on the compound or any successor seller; the honest documentation of a closed product is the legitimate end of this research.

Step 1 — fix the evidence class. Every claim about Peptide Sciences Retatrutide belongs to one class in the table above — archived listing, archived COA, registry record, dated community thread, or undated recollection. Classify first; a strong claim on weak evidence is still a weak claim. Step 2 — date the snapshot. The company's record spans roughly a decade, and documentation habits, catalog, and pricing all changed over that period. A statement true of the 2021–2023 catalog may not describe the earlier years; every conclusion in this hub carries the capture date it rests on, and yours should too. Step 3 — separate the company from its aftermarket. Anything asserted by imitator domains or successors is a claim about the present, not evidence about the original — continuity must be shown in documents, never assumed from a name. The full research method is in the peptide sciences research hub hub; Peptide Sciences Semaglutide applies the same evidence classes to a different question.

Researching a closed company means grading what survived. This table ranks the evidence types behind every claim in this hub, from strongest to weakest, so each statement can be checked against its source class.

Table: Parameter comparison: evidence types in the company record — apply it to any page in this cluster.